7-OH Products: What They Are and What Men Should Know

What 7-OH is and where it comes from

7-hydroxymitragynine, written as 7-OH, is one of the alkaloids found in Mitragyna speciosa, the tree that produces kratom. NIDA, the federal institute that funds addiction research, describes it as a metabolite the body makes from mitragynine, kratom's main alkaloid, and reports that it acts on mu-opioid receptors with substantially greater potency than mitragynine and than classical opioids including morphine.

The alkaloid in the leaf

In a living leaf, 7-OH is a trace compound. The plant does not make it in quantity. A person chewing leaf or brewing it as tea takes in mostly mitragynine, and the body converts a small share of that into 7-OH afterward. The conversion is slow, and it is limited by how much the liver can process at once.

How concentrated products are made

Retail products do not work that way. They are made by concentrating 7-OH out of plant material, or by producing it semi-synthetically, which removes the ceiling the plant imposes. The result is a tablet or a shot that delivers in one unit what the leaf could never deliver at all.

How these products differ from kratom leaf

The difference is one of kind rather than degree. Calling a concentrate a stronger version of the plant misses what changed.

What the concentration numbers mean

America's Poison Centers reports that kratom products typically contain less than 2 percent 7-OH, while semi-synthetic and synthetic products reach concentrations as high as 98 percent. The gap is not subtle. Between 1 January and 31 July 2025, poison centers logged 1,690 reports of exposures involving kratom, and state health advisories pointed at the concentrated products as the reason the pattern was shifting.

Why the label rarely says 7-OH

Packaging tends to lead with a brand name and a botanical word. Somebody reading kratom extract on the front of a box has no way to tell whether they are holding leaf material or a concentrate. For the side by side, how 7-OH differs from kratom leaf goes through it in detail.

What regular use does

Daily use of anything that activates opioid receptors produces the pattern clinicians expect from opioids, and 7-OH is no exception. The mechanism behind why dependence on 7-OH builds so quickly is covered separately. What follows is what it looks like from the outside.

Tolerance

The Food and Drug Administration's scientific assessment of 7-OH describes it as an emerging opioid threat and documents the receptor activity behind tolerance. In practice, tolerance means a product that used to have an effect stops having one, and the gap gets filled by taking more of it, more often.

What missing a dose feels like

People who have been using daily describe a stretch of feeling unwell when the next one is late. Restlessness. A running nose. Stomach trouble and broken sleep. That experience is the clearest signal that a body has adapted to the drug and now reacts to its absence.

Dependence and use disorder are different things

Physical dependence means the body has adapted and responds when the drug is gone. A substance use disorder is a clinical diagnosis about behaviour and consequences: continued use despite harm, loss of control over the amount, time lost to getting and using. A person can be dependent without meeting the criteria for a disorder. The two are assessed separately, and by a clinician rather than from a symptom list.

Where federal law stands

What follows describes the federal position on the day this page was published. This is an active rulemaking and it can move.

What the DEA has ordered

On 1 July 2026 the Drug Enforcement Administration issued two notices of intent covering 7-OH and related substances. One of those actions is finished. Mitragynine pseudoindoxyl, MGM-15 and MGM-16, three synthetic compounds derived from kratom, were placed in Schedule I under a temporary order effective 26 August 2026 and running through 26 August 2028.

What is still pending

The second action, covering 7-OH above a specified threshold, had not been ordered. The threshold proposed in the Federal Register is material containing more than 0.050 percent 7-OH by weight, or, for synthetic material, more than 1.0 milligram per article. The comment period closed on 10 September 2026. Until an order issues, 7-OH itself sits outside Schedule I at the federal level. That is a statement about scheduling, and it is not a statement about whether a product is safe.

Common myths about 7-OH products

Myth: it is strong kratom

It is one alkaloid from the plant, concentrated past anything the plant produces on its own. The difference is large. NIDA describes 7-OH as more potent at mu-opioid receptors than morphine, and the concentration figures above are the practical measure of that distance.

Myth: a product on a shelf has been reviewed by somebody

Retail availability is not a regulatory finding. The Food and Drug Administration has stated that 7-OH is not an approved drug and that no food additive regulation authorises its use in food, and it has issued warning letters to firms marketing it.

Myth: stopping is a matter of deciding to

Dependence is a physical adaptation. Willingness has little bearing on how a body responds when the drug it adapted to is absent. That makes stopping a clinical question rather than a question of resolve.

Talking to someone about it

Most people do not arrive at this page because of a crisis. They arrive because something has been nagging at them about a product in a drawer.

Signs worth taking seriously

Using to feel normal rather than to feel anything. Taking more than intended. Trying to stop and finding that day two is where it ends. Keeping the packaging out of sight. If stopping has been tried and has not held, medically supervised withdrawal from 7-OH explains why supervision changes the odds.

What a first call is

A first call is a conversation, not an admission. You can talk with the admissions team about what has been going on and what the options look like, for yourself or for somebody in your family.